CTC Bio Inc.
KKRX:0605902,705.00
KRW
0.00
(0.00%)
ISIN
KR7060590007
Return %
Stock
S&P 500
1Y
-48.18
13.14
3Y
-74.21
80.78
5Y
-70.79
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Chang-Seon Jo
- Full Time Employees
- 237
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Seoul South Korea
- IPO Date
- Feb 21, 2002
- Website
- ctcbio.com
- Similar Companies
- Business
- CTC Bio Inc. is a South Korea-based biotechnology and healthcare company primarily engaged in the research, development, manufacture, and commercialization of human pharmaceuticals, animal health products, and functional foods. Founded in 1993 and headquartered in Seoul, South Korea, the company operates through three primary business divisions: Human Pharmaceuticals, Animal Health, and Functional Foods and Bio-Ingredients. Its human pharmaceutical portfolio comprises oral dissolving film (ODF) formulations; prescription drugs across urological, cardiovascular, gastrointestinal, and central nervous system therapeutic areas; active pharmaceutical ingredients (APIs); and specialized excipients, alongside contract development and manufacturing organization (CDMO) and original design manufacturing (ODM) services. Its animal health division manufactures and distributes feed additives, including its proprietary beta-mannanase enzyme product CTCZYME; livestock microbial formulations and probiotics; veterinary pharmaceuticals such as antibiotics, antipyretics, and analgesics; anthelmintics; and agricultural disinfectants. In functional foods, the company develops and supplies probiotic supplements and bioactive dietary ingredients derived from its microbiome research facilities. CTC Bio distributes its products domestically and exports internationally across the Asia-Pacific region, Europe, the Middle East, and the Americas, maintaining commercial subsidiaries and joint venture operations abroad, including in Vietnam. In recent developments, CTC Bio obtained marketing approval from the South Korean Ministry of Food and Drug Safety in May 2024 for its novel fixed-dose combination therapy pairing clomipramine and sildenafil for the co-treatment of premature ejaculation and erectile dysfunction, while expanding its global distribution footprint through commercial agreements in regional markets such as Taiwan and reinforcing European patent protections for its urological formulations. Concurrently, the company has undergone significant shareholding and corporate governance adjustments following hostile takeover bids and substantial equity stake accumulations by PharmaResearch Co.